Rockwell wins appeal for determination as small business for Triferic NDA filing Rockwell Medical announced that it has won its appeal for size determination as a small business and is now working with the U.S. Food & Drug Administration to have its $2.2M PDUFA User Fee for filing its New Drug Application for Triferic refunded. Rockwell expects to receive a check for $2.2M from the Department of Treasury. Rockwell's NDA for Triferic was accepted for filing by the FDA on May 28. The acceptance of the NDA indicates the determination by the FDA that the application is sufficiently complete to permit a substantive review. The NDA will be subject to a standard review and will have a Prescription Drug User Fee Act action date of January 24, 2015. The PDUFA action date is the goal date for the FDA to complete its review of the NDA. The Company's NDA seeks approval for the marketing and sale of Triferic as an iron replacement therapy for the treatment of iron loss or iron deficiency to maintain hemoglobin in adult patients with hemodialysis-dependent stage 5 chronic kidney disease. During the clinical program more than 1,400 patients were treated with Triferic and more than 100K individual administrations were given. The results from the clinical trials have shown the potential for Triferic to be an effective and highly-differentiated iron delivery therapy with a safety profile similar to placebo.